Canada is no longer just an alternative market for clinical trials – it’s a strategic powerhouse. And hyperCORE’s Partner Site Network is driving that momentum.
Canada is increasingly recognized as a premier destination for clinical research, especially for sponsors prioritizing strong patient recruitment, fast startup timelines, and efficient cost management.
Cost and Incentives
The financial appeal of conducting research in Canada is strong. Clinical trial operations are approximately 15.8% less expensive than in the U.S., and the favorable 1.35* USD-CAD exchange rate further improves sponsor budgets. Sponsors can also benefit from robust government support, including tax credits (saving 25%+ for non-Canadian controlled companies between the 15% federal and 10%+ provincial tax credit) offered by the federal Scientific Research & Experimental Development (SRED) program. In addition, the Canadian Institutes of Health Research (CIHR) contributes more than $1 billion annually to support medical research infrastructure, reducing the total operational burden for sponsors and CROs.
Recruitment and Retention
Canada’s universal healthcare system and centralized medical records make it easier to identify eligible participants and maintain high retention rates. Patients are more likely to be tracked, re-engaged, and complete study protocols—reducing loss to follow-up and helping protect a trial’s endpoints. With access to a publicly funded health system, hyperCORE sites in Canada benefit from superior follow-up and longitudinal patient data, which translates into higher-quality results.
Speed
Canada’s regulatory efficiency is a game-changer. Health Canada reviews standard Clinical Trial Applications (CTAs) in just 30 days, and bioequivalence trials in a lightning-fast 7 days. This quick turnaround, combined with simultaneous ethics board reviews (yes, that’s a thing), Canadian sites can launch faster and stay ahead of global timelines. hyperCORE’s Canadian partners offer startup timelines that rival or outperform U.S. benchmarks—giving sponsors faster access to First Patient In and First Patient First Visit milestones.
Regulatory Confidence
Canada ranks among the top countries globally for active trial sites and new clinical trials. Its investigators operate under ICH-GCP standards, and data generated at Canadian sites is accepted by the FDA, EMA, MHRA, and other leading regulatory agencies.
CaRe Clinics of Canada, part of the hyperCORE network, leverages access to over 1.8 million potential patients through its affiliations with primary care and specialty practices. Located in Alberta—home to the fifth-largest integrated health system in the world—CaRe Clinics benefits from province-wide electronic health records (EHRs), standardized clinical pathways, and strong coordination between primary and specialist care, giving sponsors a significant operational advantage.
Meanwhile, Apex Trials in Ontario is also setting the pace, becoming the first site to activate in Canada on three studies in 2024 and the first globally on a Phase 2 painful diabetic neuropathy trial. With harmonized processes, shared best practices and a single point of contact, hyperCORE sites operate with the speed, consistency and collaboration that today’s Sponsors and CROs demand.
hyperCORE’s Canadian sites are ready for what’s next—whether that means remote patient monitoring, telehealth integration, or fully decentralized trial delivery. This translates into smarter feasibility, faster patient identification, and cohesive trial execution. Canada’s digital health ecosystem and coordinated infrastructure give our sites the tools they need to scale, flex, and deliver high-quality data in any trial model.
Partner with hyperCORE in Canada to access high-performing sites with strong patient recruitment, faster startup timelines, and cost-efficient trial execution.
